Eiger snaps up $7.1M to treat hepatitis

Successful CMOs achieve growth by leveraging technology. Join us for GrowthBeat Summit on June 1-2 in Boston, where we'll discuss how to merge creativity with technology to drive growth. Space is limited. Request your personal invitation here!

Eiger BioPharmaceuticals, developer of treatments for strains of hepatitis, announced that it brought in $7.1 million in first-round funding from InterWest Partners and Vivo Ventures. The Palo Alto, Calif. company will use the new money to push its lead compound — which targets hepatitis C — through its pipeline. It is also working on treatments for hepatitis D and various other viruses, it says.

Eiger spun out from research conducted on hepatitis C at Stanford University. It says the latest round of funding should give it a year’s worth of runway to continue drug testing and refinement.

VentureBeat’s VB Insight team is studying marketing analytics... Chime in here, and we’ll share the results.